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Abstract                                                            
Introduction: Many survivors of critical illness suffer long-term physical impairments, reflective 
of the significant muscle wasting that occurs during their ICU admission. It is currently unknown 
whether specific plasma miRNAs or proteins can predict which patients are susceptible to muscle 
wasting. 
 
Aims: To measure if specific miRNAs and circulating proteins exhibit a change in their molecular 
profiles which relates to muscle wasting in critically ill adults. 
 
Subjects and Methods: In this exploratory sub-study, critically ill patients were enrolled from 
three Australian ICUs. Blood samples and ultrasound-derived muscle size were collected at 
baseline (within 48-hours of enrollment), day 7, day 14 and ICU discharge. MiRNAs and protein 
concentrations known to relate to muscle mass or strength were assayed. Data are mean (SD) or 
median [IQR]. 
 
Results: Thirty-five patients were included (mean age 58 (17) years). Muscle loss from baseline 
to ICU discharge was significant (2.9 (1.2) to 2.4 (0.8) cm (n= 25); p<0.001). There were 
significant increases in miR-422a concentrations baseline to day 14 (p=0.01) and baseline to ICU 
discharge (p=0.0001). There was no change from baseline in miR-1 or miR-133a concentrations. 
GDF-15 increased significantly from baseline to day 7 (p=0.0001). No association was found 
between baseline miRNAs levels and muscle loss from baseline at day 7. Baseline concentrations 
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of GDF-15 were inversely correlated with % muscle loss at day 7 (r=-0.405). The absolute change 
in concentrations of MiR-422a, GDF-15 and IGF-1 showed a moderate to weak correlation with 
muscle loss from baseline to day 7 (r=0.312; 0.408; 0.440 respectively).   
 
Conclusion: This study showed that plasma miRNA-422a, GDF-15 and IGF-1 may provide useful 
biomarkers for muscle wasting. These results improve the current understanding of muscle loss in 
the ICU and permits the improved targeting of certain interventions which ameliorate the 















Critically ill patients admitted to an Intensive Care Unit (ICU) experience acute muscle wasting 
which increases their risk of developing long-term ICU related disorders1 such as ICU-acquired 
weakness (ICU-AW)2. ICU-AW is associated with a prolonged duration of mechanical ventilation 
and affects the ability for patients to return to pre-ICU activities, limiting common aspects of daily 
life3-5. Findings from observational data reports that 69% of mechanically ventilated patients in 
ICU admission for greater than 48 hours, are restricted in performing daily activities one year after 
discharge6. The majority of these critically ill survivors experience early and rapid muscle wasting 
within 7 days of ICU admission7, which is likely to contribute to the poor functional outcomes and 
impaired recovery8 reported in this population. Common measures of muscle size (functional 
magnetic resonance imaging9 and dual-energy X-ray absorptiometry10) cannot be easily used in an 
ICU setting due to patient immobility and radiation dosage. Therefore, ultrasound imaging has 
gained popularity as a practical and reliable tool that can quantify muscle loss at the bedside. Two 
prospective observational studies in critically ill adults have shown significant muscle loss when 
measured using ultrasonography; Parry et al. reported 10.3% reduction of the quadriceps muscle 
by day 7 of ICU admission11, and Puthucheary et al. reported a 30% reduction of the rectus femoris 
cross sectional area by day 1012. Furthermore, studies in patients with traumatic brain injury13 and 
acute respiratory distress syndrome14, 15 demonstrate that patients that lose less muscle have 
improved long-term recovery. Hence having the ability to predict the patient’s trajectory of muscle 
loss using a biomarker would enable the early application of suitable therapies (nutritional16, 17, 
physical and occupational therapy18 and electrostimulation19) to help attenuate muscle wasting, 
thus improving the functional recovery of these patients. 
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Potential biomarkers associated with muscle wasting are likely to be those involved in muscle 
protein turnover, either those that promote muscle protein synthesis or degradation; as well as 
molecules that are released into circulation during muscle degradation. Ribosomal20, 21and 
proteasomal22pathways are altered in response to certain factors such as immobility23, 
inflammation24, pharmaceutical drugs25, ageing26, and starvation27 leading to a decrease in rates of 
muscle protein synthesis and increase in muscle protein breakdown. The potential role of a number 
of these circulating proteins and miRNA as biomarkers has been explored in other conditions in 
which muscle wasting occurs. 
 
GDF-15 is a stress molecule produced in response to inflammatory and metabolic stress placed on 
mitochondria28 when excessive damage or disease occurs. Plasma concentrations of GDF-15 have 
been shown to increase with age, are inversely associated with physical activity29, and are higher 
in patients with sarcopenia or muscle atrophy30. An observational study in high-risk cardiovascular 
surgical patients compared those with established ICU-AW (n=20) and those without (n=7) 
reported that plasma GDF-15 concentrations were higher in patients with ICU-AW31. They also 
demonstrated that treatment of C2C12 myotubes (cell-culture) over a four day period with GDF-
15 (50ng/mL) increased expression of genes relating to muscle atrophy31 and resulted in 
downregulation in expression of miRNAs known to be involved in muscle homeostasis (miR-133a 
and miR-1)31. Further, a prospective longitudinal observational study by Bloch et al. observed pre-
and post-operative (days 1, day 2)  plasma samples of forty-two patients undergoing high-risk 
cardiothoracic surgery, reporting elevated post-operative levels in all patients32. Measurements 
were additionally preformed at day 7 and showed that sustained levels were only present in patients 
who developed muscle wasting, with GDF-15 concentrations returning to their baseline values in 
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the non-wasting group32. Collectively, this data suggests that GDF-15, either by down-regulating 
muscle promoting miRNAs or by directly causing muscle atrophy, is a key instigator of muscle 
wasting.  
 
Furthermore, unpublished data from our collaborators at Imperial College, London shows that 
several other proteins are associated with increased or decreased muscle mass and/or strength in 
ICU patients following aortic surgery (Table 1). These include: TXNDC12 (antioxidant protein); 
CRLF1-CHRL1 (circulating co-receptors); Mammaglobin-B and Lipocalin-2 (regulators of 
steroid activity); Resistin (insulin-signaling); FSTL3 (cell signaling); and Stanniocalcin-1 
(mitochondrial function). These regulators of muscle mass and strength may also play a role in 
muscle wasting in a heterogenous population of critically ill patients.   
 
Table 1: Correlation between circulating proteins and muscle mass or strength. 
Protein  TXNDC12 Lipocalin-2 Stanniocalcin-1 GDF-15 
Correlation between 
concentration levels 
(pg/mL) and muscle 
loss/strength 
 
Negative  Positive  Positive Positive  
Cross-sectional area 
(CSA) of the quadricep 
muscle or strength grip 
test (dynamometer)  
Rectus femoris 
CSA loss % 
Rectus femoris 
CSA loss % 




CSA loss % 




MiRNAs are small noncoding RNA molecules, consisting of between 18-28 nucleotides33. They 
play a major role in the post-transcriptional regulation and degradation of messenger RNA and 
their potential as a biomarker to predict muscle wasting has been demonstrated in other 
populations. In patients undergoing cardiac surgery, pre-surgical concentrations of miR-422a 
expression in the quadriceps muscle tissue were reported to be positively associated with both 
strength and the rectus femoris cross-sectional area (RFCSA)
34. Furthermore, those patients with the 
greatest muscle loss (>10% of RFCSA over 7 days) had lower concentrations of miR-422a 
expression34. MiR‐422a concentrations (quadriceps muscle tissue) in stable COPD patients are 
reported to be elevated when compared to healthy controls. Interestingly, the same study observed 
plasma levels of miR-422a and reported a negative association with a loss of strength in COPD 
patients34. Plasma concentrations of two muscle-specific miRNAs (myomirs) miR-1 and miR-
133a are higher in patients with stable COPD (n=103) when compared to their age-matched 
controls (n=25)35. Contrarily, plasma levels of the same miRNAs were shown to be reduced in 
patients with established ICU-AW31. These opposing results between plasma myomirs amongst 
stable COPD and ICU-AW patients may reflect disease severity, with the advancement of muscle 
wasting specific aliments (ICU-AW) greatly diminishing the size of muscle that these myomirs 
are released from, this being demonstrated in lower plasma levels. 
 
Overall, increased expression of miRNA in patients with COPD, cardiac disease and ICU-AW 
may reflect the loss of muscle mass making circulating levels of these miRNAs’ potential 
biomarkers for muscle wasting. While these biomarkers have been demonstrated to be associated 
to muscle wasting in these other states, there is limited evidence on the putative role played by 
these potential biomarkers in a heterogenous cohort of critically ill patients. Hence, the aim of this 
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thesis was to investigate relationships between miRNAs and circulating proteins and muscle 
wasting in general critically ill adults.  
 
The specific aims of this thesis were to:  
(1) Quantify changes in concentrations of circulating plasma miRNAs (miR-1, miR-422a and 
miR-133a) and circulating proteins (GDF-15, Stanniocalcin-1, CHRL1, CRLF1, 
Lipocalin-2, Resistin, IGF-1, FSTL3) in mechanically ventilated critically ill adults over 
the ICU admission. 
(2) Quantify changes in muscle size measured using ultrasound over the ICU admission. 
(3) Determine whether baseline concentrations of miRNAs and circulating proteins predict the 
degree of muscle wasting. 
(4) Determine if the change in miRNAs and circulating proteins levels from baseline to day 7 
are associated with the degree of muscle wasting over the same time period in critically ill 
adults. 
 
The hypotheses for this thesis are: 
1. There will be an increase in circulating miRNA and protein concentrations from baseline 
to day 7, 14 and ICU discharge. 
2. Muscle loss will occur over the ICU admission. 
3. There will be an association between baseline concentrations of miRNAs and circulating 
proteins and the amount of subsequent muscle wasting from baseline to day 7.  
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4. There will be a relationship between the degree of change in miRNA and circulating 















This study (MUSCLE-PRO) was a multi-centre exploratory sub-study part of a 120-patient 
randomised controlled feasibility trial (TARGET Protein feasibility trial). The TARGET Protein 
feasibility trial was conducted at six sites in Australia and New Zealand and compared augmented 
versus standard protein delivery in critically ill adult patients with the primary aim of achieving 
separation in delivered protein doses between the two groups. Three of the six sites participated in 
this MUSCLE-PRO sub-study. The Royal Adelaide Hospital Human Research Ethics Committee 
approved the study (HREC Reference number: HREC/18/CALHN/658) and governance was 
approved at each site. 
 
Patient recruitment 
Patients that were enrolled into the TARGET Protein feasibility trial at the three participating sites 
were approached for consent into the MUSCLE-PRO sub-study within 48 hours of enrolment into 
the TARGET Protein feasibility trial. Figure 1 is a consort diagram of the recruitment process. 
Study procedures were explained to the patient’s Next of Kin and a signature for consent was 
obtained. Patients were eligible for the TARGET Protein feasibility trial and the MUSCLE-PRO 







Inclusion criteria TARGET Protein feasibility trial: 
1. Aged ≥18 years. 
2. Receiving invasive mechanical ventilation. 
3. About to commence enteral nutrition (EN) or EN commenced within the previous 12 
hours. 
4. Expected to be receiving EN in ICU until at least the day after tomorrow. 
 
Exclusion criteria TARGET Protein Feasibility trial: 
1. Expected to be receiving any oral nutrition before the calendar day following 
randomisation. 
2. Any EN or parenteral nutrition (PN) received for >12 hours in this ICU admission. 
3. Previously enrolled in this study. 
4. Treating clinician considers the EN goal rate (i.e. 1ml/kg of ideal body weight (IBW) per 
hour) to be clinically contraindicated e.g. requirement for fluid restriction. 
5. Requirement for specific nutritional therapy as determined by the treating doctor or 
dietitian i.e. TARGET Protein protocol EN not considered to be in the best interest of the 
patient. 
6. Death is deemed to be imminent or inevitable during this admission and either the attending 
doctor, patient or substitute decision maker is not committed to active treatment. 





All patients admitted into the MUSCLE-PRO sub-study were additionally screened for eligibility 
based on the following criteria: 
 
Inclusion criteria MUSCLE-PRO: 
1. Enrolled into the TARGET Protein feasibility trial. 
2. Able to obtain consent and complete baseline measures within 48 hours of enrolment into 
the TARGET Protein feasibility trial.  
 
Exclusion criteria MUSCLE-PRO: 
1. Patients are unable to have quadriceps measured (e.g. burns, femoral shafts, above knee 
amputations, prone ventilated). 
 
Patient demographics 
Patient demographic data was extracted from the TARGET Protein Feasibility trial database which 
included patient age, sex, pre-existing chronic co-morbidities and Acute Physiology Chronic 
Health Evaluation II score (APACHE II)36, APACHE III diagnostic code, ideal/actual body 
weight, Body Mass Index and ICU/hospital length of stay.  
 
Study procedures 
Ultrasound images and blood samples were obtained at baseline (within 48-hours of enrollment 
into MUSCLE-PRO), days 7 and 14 whilst the patient remained in ICU, and ICU discharge 
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censored at day 28. Samples were centrifuged at 3200rpm for 10 minutes with 3-4ml of plasma 
pipetted into a 5.0 mL Eppendorf tubes for immediate storage in a -80°C freezer for future analysis. 
 
Ultrasound of muscle size: 
Ultrasound images of the quadriceps muscle layer thickness (QMLT) were taken by a qualified 
clinician with expertise in ultrasound measurement using previously described technique37. All 
bedside ultrasound measurements were taken on the right-side of the body unless the patient 
presented with existing barriers to measurements (e.g. burns or amputations), in which case the 
left-side was used. A portable 5-13 MHz and 15-6 MHz transducer was used to measure QMLT. 
Patients were positioned supine with their legs laid straight in the extended position. All 
measurements were taken (i) at the border between the lower third and upper two-thirds between 
the Anterior Superior Iliac Spine (ASIS) and the upper pole of the patella, and (ii) at the midpoint 
between the ASIS and the upper pole of the patella37. The transducer was held perpendicular to 
the skin with minimal pressure applied and still images taken in triplicate. QMLT was measured 
on the still image from the superficial muscle-muscle interface and via the bone-muscle interface. 
Three measurements were taken at the two mentioned landmarks above with the means of these 
three measurements used to determine a total means for each landmark. The means of these two 
measurements was then used to provide a total mean QMLT. 
 
Plasma protein analysis 
The eight proteins of interest were assessed using the sandwich enzyme-linked immunosorbent 
assay (ELISA) method. Plasma samples and reagents were brought to room temperature and 
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pipetted into wells with a capture antibody. The wells were washed following an incubation period. 
Biotinylated detection antibody was added followed by an incubation period at 37°C. Unbound 
biotinylated antibody was washed away with horseradish peroxidase-conjugated streptavidin 
being pipetted to the wells directly after. Wells were then washed again, tetramethylbenzidine 
substrate solution was added to develop the well colour. Incubation of plates was left at room 
temperature on a gentle agitator until colour intensity in sample wells had reached a contrast 
similar to that of our standard curve, but had not exceeded the colour intensity of the most 
concentrated reference well. A Stop Solution was then added to prevent further color development 
and samples were read at an absorbance wavelength (reference channel) of 650nm immediately 
on the Tecan Spark multimode microplate reader.  
 
Plasma miRNA extraction and quantification 
MiRNA extraction involved diluting the plasma with a denaturing solution. For this, we added 4ml 
Qiazol Lysis from the Qiagen mi-RNeasy kit to 400 µL of plasma sample. Aqueous and organic 
phase separation was achieved via the addition of 800µL of chloroform followed by centrifugation 
at 4000rpm for 25min at 4°C. 3ml of ethanol was then added to the samples and 700µL was 
collectively transferred to RNeasy Mini Columns and centrifuged for 15seconds at 8000rpm until 
all the mixture was used. Flow through was discarded with the final transfer of the RNeasy Mini 
Column to a new collection tube were RNA samples were eluted from the column by 50µL of 




Following RNA extraction, subsequent cDNA synthesis and miRNA profiling was carried out by 
qRT- PCR. Stem-loop reverse transcription primer method was used for the conversion of cDNA 
from miRNA due to its high sensitivity and specificity in recognising mature miRNA38. Real-time 
PCR was run in duplicate with the TaqMan Universal PCR Master Mix. The amplification reaction 
ran on the Applied Biosystems FAST 7500 Fast Real-Time PCR System. Endogenous normalisers, 
RNU48 and U6 were used to normalise the data for RNA extraction39. The plotting of the cycle 
threshold (Ct) values allowed us to best fit the curve using the endogenous miRNA as approximate 
copies from the obtained patient’s plasma samples. 
 
Outcomes 
The MUSCLE-PRO sub-study outcomes included: 
(1) Concentration of plasma miRNAs (miR-1, miR-422a and miR-133a) and circulating proteins 
(GDF-15, Stanniocalcin-1, CHRL1, CRLF1, Lipocalin-2, Resistin, IGF-1, FSTL3) at baseline, day 
7, day 14 and ICU discharge in mechanically ventilated critically ill adults.  
(2) Change in QMLT from baseline to day 7, day 14 and ICU discharge. 
(3) Correlation between baseline concentrations of miRNAs and circulating proteins and change 
in QMLT from baseline to day 7. 
(4) Association between change in miRNAs and circulating proteins from baseline to day 7 and 





Data and statistical analysis 
This was an exploratory study, and thus no sample size calculation was conducted. The data is 
presented as mean, standard deviation (SD) for normally distributed data, and median-Interquartile 
Range [IQR] for non-parametrically distributed data with a 5 to 95% percentile score, unless 
otherwise stated. Baseline and subsequent (day 7, day 14 and ICU discharge) concentrations were 
compared using Wilcoxon matched pairs signed rank test. The total average QMLT between the 
midpoint and upper 2/3 ultrasound image was evaluated as an outcome at day 7, 14 and ICU 
discharge and compared to the patient’s baseline thickness. A two-way ANOVA compare this 
outcome and a Bonferroni multiple comparison was used for post-test correction. Pearson’s 
correlation coefficient was calculated to identify significant associations where appropriate. 
MiRNA levels were logarithmically transformed to produce a normal distribution and stabilise for 
unwanted variance40. Statistical analysis and graph configuration were carried out on GraphPad 











This thesis represents only a partial analysis of miRNAs and circulating proteins due to limitations 
of time in an honours year. miR-1, miR-133a and miR-422a, Lipocalin-2, Resistin, FSTL3, 
Stanniocalcin-1, GDF-15, CHRL1, CRLF1 and IGF-1 have been analysed. MiR-181a, miR-499 
and miR-206; circulating proteins - Mammaglobin B, Catalase, Myostatin, Carbonic anhydrase 3, 
TNNI2, CSRP3 and TXNDX12 are currently being analysed and will be included in the final 
publication.  
 
Patient demographics and clinical outcomes 
Trial recruitment occurred between April and July 2019. In total, 35 of the 70 patients enrolled in 
the TARGET Protein feasibility trial at three sites met the inclusion criteria for recruitment into 
the MUSCLE-PRO sub-study and had consent obtained within 48 hours of randomisation. The 





















Table 2: Patient demographics and clinical characteristics 
APACHE = Acute Physiology and Chronic Health Evaluation, ICU = Intensive Care Unit, 









Age, years, mean (SD)  58 (17.77) 
Sex, Male: Female  
 
25:10 
APACHE II score, median [IQR] 22 [18-27] 




























ICU LOS, days, median [IQR] 9 [4-17] 
Hospital LOS, days, median [IQR] 18 [12-35] 
Actual Body Weight (kg), median [IQR] 87 [80-103] 
Ideal Body Weight (kg), median [IQR] 69 [58-73] 




















QMLT =Quadriceps Muscle Layer Thickness, D7= Day 7, D14= Day 14, ICU D/C = Intensive 




 (n=70) Met the MUSCLE-PRO sub study inclusion 
and exclusion criteria 
 
MiRNA/protein sampling 
• Baseline  (n=33)  
• D7  (n=14)  
• D14 (n=6)  
• ICU D/C (n=3)  
                  Excluded: 
• (n=50) due to specific inclusion and 
exclusion criteria for MUSCLE-PRO sub 
study 
(n=120) TARGET Protein patient screening for MUSCLE-PRO sub-study  
(n=35) patients recruited into the MUSCLE-PRO 
                  Excluded: 
• (n=30) no consent 
• (n=2) unable to have quadriceps measured 
• (n=2) death prior to consent  
• (n=1) unable to take blood sample 
Collection of Ultrasound QMLT Images 
• Baseline   (n=25) 
• D7            (n=14)  
• D14          (n=4) 
• ICU D/C  (n=7) 
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Plasma miRNA and circulating protein profiles at baseline, day 7, day 14 & ICU Discharge 
Analysis of miR-422a expression showed a significant rise from baseline to day 14 (p=0.01) and 
ICU discharge (p=0.0001) (Figure 2). Relative levels of miR-1 and miR-133a did not significantly 
vary from baseline to any of the other timepoints. 
 
















































































































































Figure 3: Relative plasma microRNAs were presented in a log transform  and associated against  the following
time points, Baseline (n=33), Day 7 (n=14), Day 14 (n=6) and ICU D/S ( n=3). Data presented as box and whisker plots
with median, interquartile ranges and 5 to 95% percentiles. "*P <0.01, ***P <0.0001, ns - not significant.Wlicoxon
matched-pairs signed rank test was used for caculating change in concentration over timepoints.
 
Data presented as box and whisker plots with median [interquartile range] and 5 to 95% 
percentiles. "*P <0.01, ***P <0.0001, ns - not sig ificant. Wilcoxon matched pairs signed rank 
test was used for calculating change in concentration over timepoints. Baseline (n=33), day 7 
(n=14), day 14 (n=6) and ICU discharge (n=3). 
 
 





Day 7  
n=14 




miR-1 -1.16 [-1.50-0.84] -1.32 [-1.72-0.61] -0.41[-0.81-0.08] -0.44[-0-92-0.27] 
miR-422a -1.04 [-1.15-0.64] -0.73 [-1.36-0.19] 0.13 [-0.27-0.46] 0.37 [0.37-0.03] 
miR-133a 0.80 [0.39-1.05] 0.55 [0.15-1.10] 0.81 [0.48-0.87] 0.87 [0.54-1.04] 






Circulating Proteins  
Two proteins increased in their concentrations over the ICU stay: plasma concentration of GDF-
15 was significantly higher at day 7 compared to baseline (p<0.0001: Figure 3), as was the 
concentration of Stanniocalcin-1 at ICU discharge (p<0.0001) when compared to baseline. In 
contrast, IGF-1 plasma levels were significantly lower (p<0.001) at day 14 compared to day 7. 
There were no significant changes in median concentrations values for Resistin, FSTL3, CHRL1, 
CRLF1 and Lipocalin between time-points (baseline to ICU discharge).  
 












GDF-15 2137 [1419-5576] 4339 [2058-6143] 2159 [1847-4064] 4534 [3997-5837] 
Stannio-calcin-1 225 [102-278] 143 [91-310] 85 [78-121] 880 [624-1135] 
CHRL1 2768 [1858-3995] 2527 [1649-3303] 1793 [1682-5082] 2044 [1860-4113] 
CRLF1 304 [212-416] 295 [178-373] 310 [230-373] 307 [184-365] 
Lipocalin-2 599 [346-1295] 747 [502-1074] 487 [407-594] 1250 [759-1390] 
Resistin 1793 [1241-2123] 1677 [1340-2076] 1115 [761-1953] 2126 [1701-2287] 







 42074 [27078-   
46037] 





































































































































































































































































































































Data presented as box and whisker plots with median, interquartile ranges and 5 to 95% 
percentiles. **P <0.001, ***P <0.0001, ns - not significant. Wilcoxon matched pairs signed 
rank test was used for calculating change in concentration over timepoints. Baseline (n=33), 
day 7 (n=14), day 14 (n=6) and ICU discharge (n=3). 
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Ultrasound measurements of quadriceps muscle layer thickness 
Ultrasound scans were performed on all 35 patients at baseline 2.9(SD, 1.0); however, 10 patients 
only provided a baseline image with no follow-up scan obtained. Therefore, only patients with a 
follow-up scan from baseline (e.g. baseline to day 7, baseline to day 14 and baseline to ICU 
discharge) could be included in this two-point analysis. A baseline QMLT means of 2.9 (SD 1.2) 
was established for 25 patients with their corresponding final measurement being 2.4 (SD 0.8) 
(Table 5). 
 





Day 7  
n=14 






QMLT, cm 2.9(SD, 1.0) 2.6(SD, 1.1) 2.8(SD, 1.1) 1.9(SD, 0.3) 2.4(SD, 0.8) 
QMLT=Quadricep Muscle Layer Thickness is presented as mean (SD) as data was normally 
distributed. FMT=Final measure taken 
 
In those patients with more than one measurement available, the change in means QMLT (cm) 
from baseline to the final measure conducted was significant (p<0.001: Figure 4A). Similarly, the 
decrease muscle size (17.24%) from baseline was significant for the 25 patients (p<0.001: Figure 
4B) that provided a follow-up ultrasound image from baseline. 
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Figure 2: A: Change in the ultrasound derived quadriceps muscle layer thickness from baseline to the last meausure taken in adult patients (n=25).
B: Percentage change from baseline to the last meausure taken in critically ill patients (n=25). Data alpha (**P <0.001) value was caculated from the two-way anova and a bonferroni
multiple-comparison was used for the post-test correction.
Figure 4: A: Change in the ultrasound derived quadriceps muscle layer thickness from baseline to
final measure recorded from patients (n=25).
B: Percentage change from baseline to final measure in (n=25) critically ill patients. Data alpha




A: Change in the ultrasound derived quadriceps muscle layer thickness from baseline to final 
measure (n=25). B: Percentage change from baseline to final measure in (n=25) critically ill 
patients. Data alpha (**P<0.001) value was calculated from a two-way ANOVA and Bonferroni 









Correlation between baseline miRNA and circulating protein concentrations and % change in 
quadriceps muscle layer thickness from baseline to day 7 
Baseline concentrations for both myomirs, miR-1 (r= 0.158: Figure 5), and miR-133a (r= 0.085), 
showed no correlation with the percentage of muscle loss from baseline to day 7. Similarly, there 
was no correlation with baseline values for miR-422a (r= 0.058) and muscle loss from baseline to 
day 7.   
 
Figure 5: MiRNA levels at baseline and % change in quadriceps muscle layer thickness 
from baseline to day 7 
Figure 6: The positive and negative linear associations
were determined for the patients (n = 13) microRNA
expression and muscle loss at day 7. A calculated
Spearman's correlation was used for the corresponding
values.
microRNA-1






































































































The positive and negative linear correlation were determined for the patients (n = 13) microRNA 
expression and muscle loss at day 7. Pearson’s r value was used to determine the correlational 
coefficient. 
 
Baseline GDF-15 (r=-0.405), CHRL1 (r= -0.260), Resistin (r= -0.236) and Lipocalin-2  (r= -0.113)  
concentration were all negatively correlated with loss of muscle wasting over a 7 day period 
(Figure 6). No correlation was observed for baseline concentrations of Stanniocalcin-1 (r= 0.109), 




Figure 6: Protein levels at baseline and % change in quadriceps muscle layer thickness from 
baseline to day 7 
 
CHRL1





























































































































































A liner positive or negative correlation was identified between the following circulating proteins 
concentrations and the corresponding % of muscle loss to day 7. To determine the correlation 
with protein concentration and muscle loss, the baseline values for patients (n=13) were assessed 
with the equivalent percentage in muscle loss to day 7. Pearson’s r value was used to determine 
the correlational coefficient. 
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Correlation between change in miRNAs and circulating proteins concentrations and % change 
in quadriceps muscle layer thickness from baseline to day 7 
There was no correlation between the absolute change in either miR-1 (r= 0.154: Figure 7) or 
miR-133a (r= 0.025), and muscle loss from baseline to day 7. However, miR-422a did show a 
negative correlation with muscle wasting (r= 0.312).   
 
Figure 7: Change in miRNA levels and QMLT from baseline to day 7  







































































Correlation between the patients (n=16) change in plasma miRNA levels and the corresponding 
change in QMLT after 1-week. Pearson’s r value was used to determine the strength of this 
relationship. Baseline (BS). 
 
A moderate and weak correlation was reported between change in the following protein 
concentrations and degree of muscle wasting from baseline to day 7: GDF-15 (r= 0.408: Figure 
8); IGF-1 (r= 0.440); Resistin (r= 0.172); CRLF1 (r= 0.241) and CHRL1 (r= 0.228:). No 
correlation was found for the following proteins: Lipocalin-2 (r= 0.009), Stanniocalcin-1 (r= 









Figure 8:  Change in circulating protein levels and QMLT from baseline to day 7  




















































































































































































































Correlation between the patients (n=16) change in plasma protein levels and the corresponding 
change in QMLT from baseline to day 7. Pearson’s r value was used to determine the strength of 





This is the first study to our knowledge to measure change over time in plasma concentrations of 
miRNA and circulating proteins associated with muscle wasting in a heterogenous critically ill 
adult population. As expected, miR-422a concentrations increased from ICU admission to day 14 
and ICU discharge, while neither miR-1 or miR-133a concentrations changed over the study 
period. Previous research has only assessed these mi-RNAs from muscle at a single timepoint in 
stable COPD patients, and revealed that miR-422a, miR-1 and miR-133a concentrations were all 
elevated compared to healthy controls34, 35. In our study we may not have demonstrated a change 
over time in miRNA concentrations given the baseline measurement was taken within 48hours of 
recruitment into this study, and thus the patients miRNA concentrations may have shown 
significant change prior to the baseline measurement. Additionally, no change in either myomirs 
could be a consequence of GDF-15 proposed role in the downregulation of muscle specific 
miRNAs31, and given that our study revealed a significant rise in GDF-15 levels from baseline to 
day 7 provides another reason why no directional change was observed for either myomir. These 
results suggest future ICU studies should include analysis of miR-422a; however, the baseline time 
point may contribute to observed differences between studies.  
 
Concentrations of Resistin, CHRL1, CRLF1 and Lipocalin-2 did not change over the study period; 
however, there was a significant rise from baseline to ICU discharge for FSTL3 and Stanniocalcin-
1. GDF-15 levels were also elevated at day 7 which parallels the elevated concentrations shown in 
other studies with ICU-AW patients31. Our data suggest that IGF-1 levels are stable for the first 7 
days of ICU stay and then decline. Previous reports of critically ill patients have indicated an 
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association between reduced plasma IGF-141, severe ICU-acquired paresis42 and sepsis-induced 
catabolism43 over varying timepoints. Intriguingly, Meyer et al. showed in murine and human 
skeletal myoblast cells (cell-culture) that IGF-1 could both promote or antagonise the expression 
of muscle promoting miRNAs44 (miR-1, miR-133a and miR-206) indicating cellular cross-talk 
between proteins and miRNAs45.  
 
QMLT measurements (cm) as reported in this study was 2.9 (SD 1.2) at baseline for 25 patients 
with their final measurement recorded as 2.4 (SD 0.8). This 17.24% decrease in muscle size is 
consistent with previous reports showing a 30% reduction in 22 critically ill patients within 10 
days of ICU admission by Parry et al.11 and a 10.3% reduction reported by Puthucheary et al. in 
28 critically ill patients at the same timepoint12. Findings from our study are consistent with 
previous papers that successfully measured the amount of muscle lost in critically ill adults46, 47. 
 
In our study we found there were no correlations between miRNA-1, miRNA-133a or miRNA-
422a at baseline and subsequent muscle loss. These findings are in contrast to observations made 
by Paul et al.34 who reported that patients with higher pre‐operative levels of miR-422a (from 
muscle biopsy) lost less muscle by day 7 (r=0.57, P< 0.001). Although no increase in miR‐422a 
levels were observed from baseline to day 7 in our study, our findings reported significantly 
elevated miR-422a levels at day 14 which suggests that a longer ICU admission or a mixed cohort 
may cause the release of miR-422a concentrations to increase at a later timepoint. Additionally, 
miRNA concentrations in muscle tissue may differ to that in plasma given the function of miRNAs 
is primarily intracellular (occurring in muscle)33, 48, while plasma concentrations may only 
represent atrophy leakage from the muscle rather than specific export49. Baseline concentrations 
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of CHRL1 and Resistin had a weak and negative correlation with muscle wasting by day 7, while 
no correlation was found for CRLF1, Lipocalin-2, Stanniocalcin-1 or IGF-1. Lower baseline GDF-
15 concentrations were negatively correlated with increased muscle loss. A correlation with 
muscle strength has been reported previously; preoperative GDF-15 levels in cardiovascular and 
sarcopenia50 patients have been shown to negatively correlate with handgrip strength highlighting 
that these early sampling points may be a biomarker for identifying future muscle wasting and 
consequently strength. 
 
We found a negative correlation between change in miR-422a concentrations and muscle loss from 
baseline to day 7 (r=-0.312), but no correlation for myomirs miR-1 and miR-133a. This provides 
further evidence which suggests that miR-422a expression may be upregulated in response to 
muscle loss, but not miR-1 or miR-133a. These results differ to previous research in which plasma 
miR-1 concentrations were negatively associated with type I fibre cross sectional area (r=-0.27, 
p=0.027) when assessed in stable COPD patients35. Previous research has not specifically assessed 
plasma miR-1 and miR-133a concentrations with muscle wasting and given its identical role in 
muscle physiology in comparison to miR-1 suggests that a similar result is expected for them 
both51. No relationship for either miR-1 or miR-133a and muscle wasting (day 7) could 
additionally be due to elevated levels of GDF-15 (reported at day 7 in this study) affecting 
circulating concentrations of both myomirs31. 
 
A negative correlation for CRLF1and CHRL1 was observed for muscle loss from baseline to day 
7, while FSTL3, Resitin CRLF1, Lipocalin-2 and Stanniocalcin-1 showed no association with 
muscle wasting. It is possible that these results for the above proteins represent factors involved in 
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the acute inflammatory response of cardiac surgery and chronic inflammation in COPD and is less 
likely to be observed in a mixed cohort of ICU patients. Additionally, these results could be 
explained by the small sample size (n=13) and perhaps underestimates the putative role of these 
markers in muscle wasting. Change in GDF-15 concentrations from baseline to day 7 in our study 
was positively correlated with muscle loss. This parallels results in other ICU patients, including 
those undergoing high risk cardiothoracic surgery32 and individuals with established ICU-AW31. 
Both groups profile an increase in circulating plasma concentrations that correlates with more 
muscle wasting as ICU length of stay and their disease progresses relative to controls. 
Interestingly, healthy individuals demonstrate a similar scenario showing that when the muscle 
surpasses the threshold of what constitutes healthy activity, there is a significant increase in GDF-
15 that is associated with decreased muscle performance and increased inflammation as seen in 
post-race plasma samples of endurance athletes52. The dualistic role of GDF-15 is also observed 
in response to sepsis and demonstrated by inhibition of GDF-15 which results in greater muscle 
loss because there is less liberation of lipid from the liver53. The reason for observing a negative 
relationship between baseline GDF-15 levels is possibly owing to better management of lipid 
resources within the first 48 hours (at first sample point). However, as ICU duration and disease 
progress there is less lipid left to release, explaining why a positive correlation was established 
when we accessed change over time.  
 
Strengths and Limitations  
Although prior studies have grouped patients by their diagnostic population (aortic surgery and 
COPD), to our knowledge this is the first time that the role of miRNA/circulating proteins in 
muscle wasting has been assessed in a heterogeneous ICU cohort. Additionally, we report miRNA 
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and circulating protein concentrations throughout the ICU admission which is another first. This 
exploratory approach is advantageous for improving subsequent research questions by flagging 
what is pertinent for future investigations. 
 
This study had a few limitations. Firstly, the sample size was limited by the inclusion of patients 
from the main feasibility trial into this sub-study, resulting in a relatively small sample. In addition, 
complete data was not available for patients at all pre-specified timepoints given the differing 
length of stay of included patients, reflecting the complex nature of intensive care research. 
Therefore, only participants with baseline and day 7 values were analysed for muscle wasting; this 
diminished our sample size by 50%. As ICU patients cannot provide a plasma and QMLT test 
prior to admission this could underestimate the amount of muscle loss and biomarker 
concentrations taken at baseline. This highlights another difficulty when studying patients in the 
ICU ward. Additionally, the increase in muscle gain reported from ultrasound images for some 
patients could be explained by the variation in pressure applied between operators or the 
accumulation of oedema within the muscle tissue, which is common in critical illness54. Lastly, no 
data was analysed on potential confounding factors which include, delivered calorie and protein 
dosages and assessment of muscle strength. 
 
A perfect prognostic model for ICU-related muscle wasting does not exist. However, our 
exploratory study expands upon the current literature and broadens our current understanding 
beyond specific diagnostic groups to a more general ICU population acknowledging that acute 
muscle wasting and ICUAW can affect any critically ill patient. Our data showed that a potential 
pattern of change emerges in both circulating miRNA and proteins (miRNA-422a, GDF-15 and 
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IGF-1) which could reflect key modulating factors that drive muscle wasting in critical illness. 
These results advance our current understanding and offer an intriguing insight into the structural 
and functional changes of skeletal muscle. This permits improved targeting of certain interventions 
which ameliorate the progression of acute muscle wasting, thus avoiding the development of more 
severe ICU-related muscle disorders. 
 
Conclusion  
In this study, miR-422a, GDF-15 and IGF-1 concentrations were related to muscle wasting 
suggesting their potential role as biomarkers during ICU admission. This data paves the way for 
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